Practical Dealmaking in Discovery: The Structural Biology Case

Discovery dealmaking is by no means dead-but it's certainly been practicalized. In the last few months, one good example of a still interesting discovery area--high-throughput structural biology--has seen a flurry of dealmaking. But it's not yet frequent or rich enough to justify the venture valuations originally applied to them. And the deals themselves reflect the results-oriented conservatism of Big Pharma buyers.